Journal of Medicinal Chemistry
ARTICLE
Moch, H.; Storkel, S.; Lerman, M. I.; Linehan, W. M.; Zbar, B. Germline
and Somatic Mutations in the Tyrosine Kinase Domain of the MET
Proto-oncogene in Papillary Renal Carcinomas. Nature Genet. 1997, 16,
3-carboxamide (BMS-777607), a Selective and Orally Efficacious In-
hibitor of the Met Kinase Superfamily. J. Med. Chem. 2009, 52, 1251–
1254.
6
8–73.
(20) Albrecht, B. K.; Harmange, J. C.; Bauer, D.; Berry, L.; Bode, C.;
Boezio, A.; Chen, A.; Choquette, D.; Dussault, I.; Fridrich, C.; Hirai, S.;
Hoffman, D.; Larrow, J. F.; Kaplan-Lefko, P.; Lin, J.; Lohman, J.; Long,
A. M.; Moriguchi, J.; O’Connor, A.; Potashman, M. H.; Reese, M.; Rex,
K.; Siegmund, A.; Shah, K.; Shimanovich, R.; Springer, S. K.; Teffera, Y.;
Yang, Y.; Zhang, Y.; Bellon, S. F. Discovery and Optimization of
Triazolopyridazines as Potent and Selective Inhibitors of the c-Met
Kinase. J. Med. Chem. 2008, 51, 2879–2882.
(21) D’Angelo, N. D.; Bellon, S. F.; Booker, S. K.; Cheng, Y.; Coxon,
A.; Dominguez, C.; Fellows, I.; Hoffman, D.; Hungate, R.; Kaplan-Lefko,
P; Lee, M. R.; Li, C.; Liu, L.; Rainbeau, E.; Reider, P. J.; Rex, K.; Siegmund,
A.; Sun, Y.; Tasker, A. S.; Xi, N.; Xu, S.; Yang, Y.; Zhang, Y.; Burgess, T. L.;
Dussault, I.; Kim, T.-S. Design, Synthesis, and Biological Evaluation of
Potent c-Met Inhibitors. J. Med. Chem. 2008, 51, 5766–5779.
(22) Boezio, A. A.; Berry, L.; Albrecht, B. K.; Bauer, D.; Bellon, S. F.;
Bode, C.; Chen, A.; Choquette, D.; Dussault, I.; Hirai, S.; Kaplan-Lefko,
P.; Larrow, J. F.; Lin, M.-H. J.; Lohman, J.; Potashman, M. H.; Rex, K.;
Santostefano, M.; Shah, K.; Shimanovich, R.; Springer, S. K.; Teffera, Y.;
Yang, Y.; Zhang, Y.; Harmange, J.-C. Discovery and Optimization of
Potent and Selective Triazolopyridazine Series of c-Met Inhibitors.
Bioorg. Med. Chem. Lett. 2009, 19, 6307–6312.
(9) Jeffers, M.; Fiscella, M.; Webb, C. P.; Anver, M.; Koochekpour,
S.; Vande Woude, G. F. The Mutationally Activated Met Receptor
Mediates Motility and Metastasis. Proc. Natl. Acad. Sci. U.S.A. 1998,
95, 1441–14422.
(10) Christensen, J. G.; Burrows, J.; Salgia, R. c-Met as a Target for
Human Cancer and Characterization of Inhibitors for Therapeutic
Intervention. Cancer Lett. 2005, 225, 1–26.
(11) Smolen, G. A.; Sordella, R.; Muir, B.; Mohapatra, G.; Barmettler,
A.; Archibald, H.; Kim, W. J.; Okimoto, R. A.; Bell, D. W.; Sgroi, D. C.;
Christensen, J. G.; Settleman, J.; Haber, D. A. Amplification of MET May
Identify a Subset of Cancers with Extreme Sensitivity to the Selective
Tyrosine Kinase Inhibitor PHA-665752. Proc. Natl. Acad. Sci. U.S.A. 2006,
103, 2316–2321.
(12) Lutterbach, B.; Zeng, Q.; Davis, L. J.; Hatch, H.; Hang, G.;
Kohl, N. E.; Gibbs, J. B.; Pan, B.-S. Lung Cancer Cell Lines Harboring
MET Gene Amplification are Dependent on Met for Growth and
Survival. Cancer Res. 2007, 67, 2081–2088.
(13) Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.;
Hyland, C.; Park, J. O.; Lindeman, N.; Gale, C. M.; Zhao, X.;
Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, A. M.; Cappuzzo,
F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; J €a nne, P. A. MET
Amplification Leads to Gefitinib Resistance in Lung Cancer by Activat-
ing ERBB3 Signaling. Science 2007, 316, 1039–1043.
(23) Nishii, H.; Chiba, T.; Morikami, K.; Fukami, T. A.; Sakamoto,
H.; Ko, K.; Koyano, H. Discovery of 6-benzyloxyquinolines as c-Met
Selective Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 1405–
1409.
(14) Bean, J.; Brennan, C.; Shih, J.-Y.; Riely, G.; Viale, A.; Wang, L.;
Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W.-C.;
Yu, C.-J.; Gazdarl, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S.-F.;
Yang, P.-C.; Miller, V.; Ladanyi, M.; Yang, C.-H.; Pao, W. MET
Amplification Occurs With or Without T790M Mutations in EGFR
Mutant Lung Tumors with Acquired Resistance to Gefitinib or Erlotinib.
Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 20932–20937.
(24) Porter, J.; Lumb, S.; Lecomte, F.; Reuberson, J.; Foley, A.;
Calmiano, M.; le Riche, K.; Edwards, H.; Delgado, J.; Franklin, R. J.;
Gascon-Simorte, J. M.; Maloney, A.; Meier, C.; Batchelor, M. Discovery
of a Novel series of Quinoxalines as Inhibitors of c-Met Kinase. Bioorg.
Med. Chem. Lett. 2009, 19, 397–400.
(25) Porter, J.; Lumb, S.; Franklin, R. J.; Gascon-Simorte, J. M.;
Calmiano, M.; Riche, K. L.; Lallemand, B.; Keyaerts, J.; Edwards, H.;
Maloney, A.; Delgado, J.; King, L.; Foley, A.; Lecomte, F.; Reuberson, J.;
Meier, C.; Batchelor, M. Discovery of 4-azaindoles as Novel Inhibitors of
c-Met Kinase. Bioorg. Med. Chem. Lett. 2009, 19, 2780–2784.
(26) Buchanan, S. G.; Hendle, J.; Lee, P. S.; Smith, C. R.; Bounaud,
P. Y.; Jessen, K. A.; Tang, C. M.; Huser, N. H.; Felce, J. D.; Froning, K. J.;
Peterman, M. C.; Aubol, B. E.; Gessert, S. F.; Sauder, J. M.; Schwinn,
K. D.; Russell, M.; Rooney, I. A.; Adams, J.; Leon, B. C.; Do, T. H.;
Blaney, J. M.; Sprengeler, P. A.; Thompson, D. A.; Smyth, L.; Pelletier,
L. A.; Atwell, S.; Holme, K.; Wasserman, S. R.; Emtage, S.; Burley, S. K.;
Reich, S. H. SGX523 is an Exquisitely Selective, ATP-Competitive
Inhibitor of the MET Receptor Tyrosine Kinase with Antitumor Activity
in Vivo. Mol. Cancer Ther. 2009, 8, 3181–3190.
(15) Zou, H. Y.; Li, Q. H.; Lee, J. H.; Arango, M. E.; McDonnell,
S. R.; Yamazaki, S.; Koudriakova, T. B.; Alton, G.; Cui, J. J.; Kung, P.-P.;
Nambu, M. D.; Los, G.; Bender, S. L.; Mroczkowski, B.; Christensen,
J. G. An Orally Available Small-molecule Inhibitor of c-Met, PF-
2
341066, Exhibits Cytoreductive Antitumor Efficacy Through Antipro-
liferative and Antiangiogenic Mechanisms. Cancer Res. 2007,
7, 4408–4417.
16) Bellon, S. F.; Kaplan-Lefko, P. J.; Yang, Y.; Zhang, Y.;
6
(
Moriguchi, J.; Rex, K.; Johnson, C. W.; Rose, P. E.; Long, A. M.;
O’Connor, A. B.; Gu, Y.; Coxon, A.; Kim, T.-S.; Tasker, A.; Burgess,
T. L.; Dussault, I. c-Met inhibitors with Novel Binding Mode Show
Activity against Several Hereditary Papillary Renal Cell Carcinoma-
Related Mutations. J. Biol. Chem. 2008, 283, 2675–2683.
(
17) Zhang, Y. H.; Kaplan-Lefko, P. J.; Rex, K.; Yang, Y.; Moriguchi,
(27) Burgess, T.; Coxon, A.; Meyer, S.; Sun, J.; Rex, K.; Tsuruda, T.;
Chen, Q.; Ho, S.-Y.; Li, L.; Kaufman, S.; McDorman, K.; Cattley, R. C.;
Sun, J.; Elliott, G.; Zhang, K.; Feng, X.; Jia, X.-C.; Green, L.; Radinsky, R.;
Kendall, R. Fully Human Monoclonal Antibodies to Hepatocyte
Growth Factor with Therapeutic Potential Against Hepatocyte Growth
Factor/c-Met-Dependent Human Tumors. Cancer Res. 2006, 66,
1721–1729.
(28) Martens, T.; Schmidt, N. O.; Eckerich, C.; Fillbrandt, R.;
Merchant, M.; Schwall, R.; Westphal, M.; Lamszus, K. A Novel One-
Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In Vivo.
Clin. Cancer Res. 2006, 12, 6144–6152.
J.; Osgood, T.; Mattson, B.; Coxon, A.; Reese, M.; Kim, T.-S.; Lin, J.;
Chen, A.; Burgess, T. L.; Dussault, I. Identification of a Novel Recepteur
d’Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Anti-
tumor Activity in Vivo. Cancer Res. 2008, 68, 6680–6687.
(18) Raeppel, S.; Claridge, S.; Saavedra, O.; Gaudette, F.; Zhan, L.;
Mannion, M.; Zhou, N.; Raeppel, F.; Granger, M.-C.; Isakovic, L.;
D ꢀe ziel, R.; Nguyen, H.; Beaulieu, N.; Beaulieu, C.; Dupont, I.; Robert,
M.-F.; Lefebvre, S.; Dubay, M.; Rahil, J.; Wang, J.; Ste-Croix, H.;
Macleod, A. R.; Besterman, J.; Vaisburg, A. N-(3-Fluoro-4-(2-arylthieno-
[
3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carbox-
amides: A Novel Series of Dual c-Met/VEGFR2 Receptor Tyrosine
Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 1323–1328.
(29) Liu, X.; Yao, W.; Newton, R. C.; Scherle, P. A. Targeting the
c-MET Signaling Pathway for Cancer Therapy. Expert Opin. Invest.
Drugs 2008, 17, 997–1011.
(19) Schroeder, G. M.; An, Y.; Cai, Z.-W.; Chen, X.-T.; Clark, C.;
Cornelius, L. A. M.; Dai, J.; Gullo-Brown, J.; Gupta, A.; Henley, B.; Hunt,
J. T.; Jeyaseelan, R.; Kamath, A.; Kim, K.; Lippy, J.; Lombardo, L. J.;
Manne, V.; Oppenheimer, S.; Sack, J. S.; Schmidt, R. J.; Shen, G.;
Stefanski, K.; Tokarski, J. S.; Trainor, G. L.; Wautlet, B. S.;
Wei, D.; Williams, D. K.; Zhang, Y.; Zhang, Y.; Fargnoli, J.; Borzilleri,
R. M. Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-
fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-
(30) Migliore, C.; Giordano, S. Molecular Cancer Therapy: Can Our
Expectation be MET? Eur. J. Cancer 2008, 44, 641–651.
(31) Pan, B.-S.; Chan, G. K. Y.; Chenard, M.; Chi, A.; Davis, L. J.;
Deshmukh, S. V.; Gibbs, J. B.; Gil, S.; Hang, G.; Hatch, H.; Jewell, J. P.;
Kariv, I.; Katz, J. D.; Kunii, K.; Lu, W.; Lutterbach, B. A.; Paweletz, C. P.;
Qu, X.; Reilly, J. F.; Szewczak, A. A.; Zeng, Q.; Kohl, N. E.;
Dinsmore, C. J. MK-2461, a Novel Multitargeted Kinase Inhibitor,
4
107
dx.doi.org/10.1021/jm200112k |J. Med. Chem. 2011, 54, 4092–4108